Quarterly and annual results disclosed under 8-K Item 2.02.
BioAtla, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, BioAtla, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided an update on its ongoing clinical programs.”
AEye, Inc. reported first quarter ended March 31, 2024 results: net income $(10.2) million, EPS $(1.61) per share.
“GAAP net loss was $(10.2) million, or $(1.61) per share, based on 6.4 million weighted average common shares outstanding.”
Nuvation Bio Inc. reported the first quarter ended March 31, 2024 results: net income $14.8 million, EPS $(0.07) per share.
“For the three months ended March 31, 2024, Nuvation Bio reported a net loss of $14.8 million, or $(0.07) per share.”
Taysha Gene Therapies, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, Taysha Gene Therapies, Inc. reported financial results and business highlights for the quarter ended March 31, 2024.”
DeFi Development Corp. reported the first quarter ended March 31, 2024 results: revenue approximately $411,000, net income approximately $964,000, EPS $0.09 basic and diluted loss per share.
“our new business lines combined with our current offerings will take us in the years ahead.” Financial Results Revenue for the quarter ended March 31, 2024, was approximately $411,000 compared to approximately $467,000 for the quarter ended March 31, 2023. This decrease was primarily due to a reduction in closed loans compared to the same period in 2023.”
Eos Energy Enterprises, Inc. reported first quarter ended March 31, 2024 results: revenue $6.6 million. Guidance reaffirmed.
“zinc-based long duration energy storage systems, today announced financial results for the first quarter ended March 31, 2024. First Quarter Highlights + Revenue totaled $6.6 million from its Z3 semi-automated manufacturing line, 25% lower than prior year period, driven by customer revenue recognition timing. + Cost of Goods Sold totaled $28.2 million, a 5%”
Origin Materials, Inc. reported first quarter ended March 31, 2024 results: revenue $6.8 million. Guidance reaffirmed.
“Origin Materials reported quarterly revenue of $6.8 million generated by the Company’s supply chain activation program and joint development agreements.”
SpringBig Holdings, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.5 million, net income $0.4 million, EPS $0.01. Guidance raised.
“by 34% year-on- year and expect a continuing positive trend in our Adjusted EBITDA* margins as the year progresses.” First Quarter 2023 Financial Highlights: ● Revenue was $6.5 million, compared to $7.2 million in the prior year. ● Subscription revenue represents 83% of total revenue at $5.4 million, compared to $5.7 million in the prior year. ● Gross profit”
Oncology Institute, Inc. reported three months ended March 31, 2024 results: revenue $95 million, net income Net loss of $19.9 million, EPS $(0.22) and $(0.22). Guidance reaffirmed.
“Officer • Hired 7 new providers in the quarter and ended the quarter with 73 clinics and 126 employed providers First Quarter 2024 Financial Highlights • Consolidated revenue of $95 million, an increase of 24.2% from $76 million compared to the prior year quarter • Gross profit of $12 million, a decrease of 15.1% compared to the prior year quarter, and gross margin”
Lucid Diagnostics Inc. reported the three months ended March 31, 2024 results: revenue $1.0 million, net income $18.1 million or $(0.40) per common share, EPS $(0.40) per common share.
“regional plans in biomarker legislation states and pilots with national plans. Financial Results ● For the three months ended March 31, 2024, EsoGuard related revenues were $1.0 million. Operating expenses were approximately $11.8 million, which included stock-based compensation expenses of $0.9 million. GAAP net loss attributable to common stockholders was”
Vincerx Pharma, Inc. reported financial results for first quarter of 2024.
“On May 14, 2024, Vincerx Pharma, Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2024.”
CAPITAL SOUTHWEST CORP reported fourth fiscal quarter and fiscal year ended March 31, 2024 results: net income $0.68 per weighted average share outstanding, EPS $0.68 per weighted average share outstanding.
“Capital Southwest Announces Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2024”
TFF Pharmaceuticals, Inc. reported fiscal quarter ended March 31, 2024 results: net income Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7.
“Net loss was $5.7 million for the quarter ended March 31, 2024, a decrease of $1.4 million, compared to a net loss of $7.1 million for the year ended March 31, 2023.”
Arcutis Biotherapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $21.6 million.
“3027 Townsgate Road, Suite 300 Westlake Village, CA 91361 | arcutis.com First Quarter 2024 Summary Financial Results Product revenues for the quarter ended March 31, 2024 were $21.6 million compared to $2.8 million for the corresponding period in 2023. Revenues for the quarter were $15.0 million for ZORYVE (roflumilast) cream 0.3% and $6.5 million for ZORYVE”
Passage BIO, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $16.7 million, or $0.30 per basic and diluted share.
“Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024”
Metagenomi Therapeutics, Inc. reported quarter ended March 31, 2024 results: revenue $11,159 thousand, net income Net loss of $(25,148) thousand, EPS $(1.19) per share.
“announced its financial results for the quarter ended March 31, 2024”
Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2024.
“On May 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update.”
Strawberry Fields REIT, Inc. reported the quarter ended March 31, 2024 results: revenue $27.8 million, net income $6.0 million.
“For the quarters ended March 31, 2024, and March 31, 2023: ● FFO was $14.1 million and $11.1 million, respectively. ● AFFO was $13.1 million and $13.1 million, respectively. ● Net income was $6.0 million and $4.1 million, respectively. ● Rental income received was $27.8 million and $24.2 million, respectively.”
Korro Bio, Inc. reported first quarter of 2024 results: net income $19.6 million.
“Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2024”
Aprea Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 14, 2024, Aprea Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2024, and provided an update on the Company’s operations for the same period.”
HYDROFARM HOLDINGS GROUP, INC. reported the first quarter ended March 31, 2024 results: revenue $54.2 million, net income $12.6 million, EPS $(0.28) per diluted share. Guidance reaffirmed.
“agriculture, today announced financial results for its first quarter ended March 31, 2024. First Quarter 2024 Highlights vs. Prior Year Period: • Net sales decreased to $54.2 million compared to $62.2 million. • Gross Profit Margin increased to 20.2% of net sales compared to 18.3%. • Adjusted Gross Profit Margin (1) increased to 23.4% of net sales compared to”
Acrivon Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $16.5 million.
“Net loss for the quarter ended March 31, 2024 was $16.5 million compared to a net loss of $12.8 million for the same period in 2023.”
Monogram Technologies Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $3.5 million.
“On May 14, 2024, Monogram Orthopaedics Inc., a Delaware corporation (the “Company”) issued a press release announcing, among other things, its financial results for the three months ended March 31, 2024.”
Shuttle Pharmaceuticals Holdings, Inc. reported preliminary financial results for first quarter ended March 31, 2024.
“On May 14, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), issued a press release providing a corporate update in connection with the filing of our Quarterly Report on Form 10-Q for the period ended March 31, 2024.”
American Bitcoin Corp. reported quarter ended March 31, 2024 results: revenue $7.5 million, net income ($11.7) million.
“shareholder value and demonstrates the Board and management team’s confidence in Gryphon’s strategy.” Q1 2024 and Recent Highlights ● Total mining revenue in Q1/2024 of $7.5 million, compared to $4.8 million in Q1/2023. ● Breakeven Cost 1 per Bitcoin in Q1/2024 was $34,063, compared to $12,910 in Q1/2023. The company continues to be focused on Breakeven”
Canoo Inc. reported the first quarter ended March 31, 2024 results: net income $(110.7) million, EPS $(1.13) per share. Guidance reaffirmed.
“On May 14, 2024, Canoo Inc. (the “Company”) issued a press release announcing certain financial and other results for the first quarter ended March 31, 2024.”
REVIVA PHARMACEUTICALS HOLDINGS, INC. reported first quarter ended March 31, 2024 results: net income approximately $7.4 million, EPS $0.25 per share.
“The Company reported a net loss of approximately $7.4 million, or $0.25 per share, for the three months ended March 31, 2024”
Adicet Bio, Inc. reported first quarter ended March 31, 2024 results: net income net loss of $28.0 million, EPS $0.35 per basic and diluted share.
“Net loss for the three months ended March 31, 2024 was $28.0 million, or a net loss of $0.35 per basic and diluted share”
T Stamp Inc reported the three months ended March 31, 2024 results: revenue $574 thousand, EPS $0.26 per share.
“were undertaken to maximize future revenue potential from that relationship, but our net revenue still increased from $459 thousand for the three months ended March 31, 2023 to $574 thousand for the three months ended March 31, 2024. The increase in net revenue included an additional $115 thousand revenue from our S&P 500 bank customer adopting the Orchestration”
Hall of Fame Resort & Entertainment Co reported the quarter ended March 31, 2024 results: revenue $4.2 million, net income $14.9 million, EPS ($2.30).
“First quarter revenue was $4.2 million, an increase of 34% compared to the same period in the prior year”
Serina Therapeutics, Inc. reported the quarter ended March 31, 2024 results: revenue $5,000 and $30,000 for the first quarter of 2024 and in the same period in 2023, respectively, net income $9.4 million, or ($3.38) per share (basic and diluted), EPS ($3.38) per share (basic and diluted).
“On May 14, 2024, the Company announced its financial results for the quarter ended March 31, 2024.”
Motus GI Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $64,000, net income $7.6 million, or $0.88 per basic and diluted share, EPS $0.88 per basic and diluted share.
“The Company reported revenue of $64,000 for the first quarter of 2024, compared to $56,000 for the same period last year.”
ENDRA Life Sciences Inc. reported the three months ended March 31, 2024 results: net income $2.8 million, or $0.26 per share, EPS $0.26 per share.
“Net loss in the first quarter of 2024 was $2.8 million, or $0.26 per share, compared with a net loss of $2.9 million, or $0.93 per share, in the first quarter of 2023.”
Absci Corp reported the quarter ended March 31, 2024 results: revenue $0.9 million, net income $22.0 million.
“Revenue was $0.9 million for the three months ended March 31, 2024 compared to $1.3 million for the three months ended March 31, 2023.”
Enliven Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $22.7 million.
“Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update”
Poseida Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 14, 2024, Poseida Therapeutics, Inc. (the “Company”) issued a press release announcing its updates and financial results for the first quarter ended March 31, 2024.”
DermTech, Inc. reported the quarter ended March 31, 2024 results: revenue $3.8 million, net income Net loss was $20.0 million, EPS ($0.58) per share.
“First-Quarter 2024 Financial Results • Billable sample volume declined 14 percent from the first quarter of 2023 to approximately 15,360. • Test revenue was $3.7 million, up 7 percent from the first quarter of 2023, primarily due to a higher ASP for the DMT. • Total revenue was $3.8 million, an 11 percent increase from the first quarter of 2023, driven by higher test revenue. • Cost of test revenue was $3.1 million, a 19 percent decrease from the first quarter of 2023, yielding a test gross margin of 16 percent, compared to negative 11 percent for the first quarter of 2023. Cost of test revenue decreased primarily because of lower employee-related costs. • Sales and marketing expenses were $7.8 million, a 49 percent decrease from the first quarter of 2023. The decrease was primarily attributable to lower employee-related and marketing expenditures. • Research and development expenses were $3.3 million, a 26 percent decrease from the first quarter of 2023, largely due to lower employee-”
Bolt Biotherapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 14, 2024, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024 and a corporate update.”
iANTHUS CAPITAL HOLDINGS, INC. reported first quarter ended March 31, 2024 results: revenue $41.6 million, net income net loss of $14.0 million, EPS net loss of less than $0.01 per share.
“in accordance with U.S. generally accepted accounting principles (“GAAP”). All currency is expressed in U.S. dollars. First Quarter 2024 Financial Highlights • Revenue of $41.6 million, a sequential increase of 1.7% from Q4 2023 and an increase of 13.1% from the same quarter in the prior year. • Gross profit of $17.2 million, a sequential increase of 8.1% from”
Associated Capital Group, Inc. reported the first quarter ended March 31, 2024 results: revenue 3,011, net income 13,821, EPS 0.64.
“Financial Highlights ($ in 000's except AUM and per share data) (Unaudited) Three Months Ended March 31, 2024 2023 AUM - end of period (in millions) $ 1,549 $ 1,799 AUM - average (in millions) 1,556 1,841 Revenues 3,011 2,465 Operating loss before management fee (Non-GAAP) (2,988 ) (2,590 ) Investment and other non-operating income/(loss), net 22,625 24,735 Income/(loss) before income taxes 17,655 19,602 Net income/(loss) 13,821 17,754 Net income/(loss) per share-diluted 0.64 0.81 Class A shares outstanding (000's) 2,469 2,975 Class B " " 18,951 18,963 Total " " 21,420 21,938 Book value per share $ 42.80 $ 41.30”
Ovid Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024.
“Ovid Therapeutics Inc. (the "Company") issued a press release announcing Business Update, First Quarter 2024 Financial Results.”
Flutter Entertainment plc reported the quarter ended March 31, 2024 results: revenue $3,397 million, net income ($177) million, EPS ($1.10) per share. Guidance reaffirmed.
“Key financial highlights: In $ millions except percentages and average monthly players Three months ended March 31 2024 2023 YOY Average monthly players (AMPs) (‘000s) 2 13,722 12,349 +11 % Revenue 3,397 2,918 +16 % Net loss (177 ) (111 ) (59 %) Adjusted EBITDA 3,4 514 352 +46 % Adjusted EBITDA Margin 3 15.1 % 12.1 % +310bps Net loss per share ($) (1.10 ) (0.58 ) (92 %)”
ESSA Pharma Inc. reported fiscal second quarter ended March 31, 2024 results: net income $9.0 million.
“Net Loss. ESSA recorded a net loss of $9.0 million for the second quarter ended March 31, 2024 compared to $7.1 million for the second quarter ended March 31, 2023.”
PAVmed Inc. reported three months ended March 31, 2024 results: revenue $1.0 million, net income $22.8 million, EPS $(2.62) per common share.
“well in furtherance of this revised strategy.” Highlights from the first quarter and recent weeks include : ● Yesterday, Lucid reported that 1Q24 EsoGuard ® revenue was $1.0 million, which was flat compared to 4Q23 and represents a 124 percent increase from 1Q23. ● Strengthened balance sheet by Lucid’s completion of a $29.8 million Series B Preferred Stock”
Boot Barn Holdings, Inc. reported fiscal year ended March 30, 2024 (52 weeks) results: revenue Net sales increased 0.6% over the prior-year to $1.667 billion., net income Net income was $147.0 million, or $4.80 per diluted share, EPS $4.80 per diluted share.
“For the fiscal year ended March 30, 2024 (52 weeks) compared to the fiscal year ended April 1, 2023 (53 weeks): ● Net sales increased 0.6% over the prior-year to $1.667 billion.”
Boot Barn Holdings, Inc. reported fourth fiscal quarter ended March 30, 2024 (13 weeks) results: revenue Net sales decreased 8.7% over the prior-year period to $388.5 million., net income Net income was $29.4 million, or $0.96 per diluted share, EPS $0.96 per diluted share.
“Presentation is available at investor.bootbarn.com. For the quarter ended March 30, 2024 (13 weeks) compared to the quarter ended April 1, 2023 (14 weeks): ● Net sales decreased 8.7% over the prior-year period to $388.5 million. Net sales decreased 2.2% when excluding $28.3 million of sales from the 14th week of the prior-year period. ● Same store sales”
scPharmaceuticals Inc. reported first quarter ended March 31, 2024 results: revenue $6.1 million, net income $14.1 million.
“(EX-99.1) --- EX-99.1 Exhibit 99.1 scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host”
Superior Drilling Products, Inc. reported the first quarter ended March 31, 2024 results: revenue $ 4,946, net income $ (1,822), EPS $ (0.06).
“31, 2023 March 31, 2023 Change Sequential Change Year/Year North America $ 4,249 $ 3,639 $ 5,475 16.8 % (22.4 )% International 697 633 806 10.1 % (13.5 )% Total Revenue $ 4,946 $ 4,273 $ 6,281 15.8 % (21.3 )% Tool (DNR) Revenue $ 2,981 $ 2,512 $ 4,254 18.7 % (29.9 )% Contract Services 1,965 1,761 2,027 11.6 % (3.1 )% Total Revenue $ 4,946 $ 4,273 $ 6,281”
SKYX Platforms Corp. reported the first quarter ended March 31, 2024 results: revenue $19.0 million, net income $9.7 million, or $(0.10) per share, EPS $(0.10) per share.
“SKYX Reports Record First Quarter Sales of $19.0 Million Compared to $18.6 Million for First Quarter 2023 as it Continues to Grow its Market Penetration in the U.S and Canada of its Advanced and Smart Platform Products”
Atea Pharmaceuticals, Inc. reported financial results for three months ended March 31, 2024.
“On May 14, 2024, Atea Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the three months ended March 31, 2024”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.